Divalproex Sodium Market - Size, Share, Outlook, and Forecast till 2026

Divalproex sodium is used as a medication to treat certain types of seizures such as epilepsy, either independently or in combination with other medication. This medicine is an anticonvulsant that works in the brain tissue to stop seizures. Divalproex sodium is also indicated for treatment of manic episodes related to bipolar disorder and used to prevent migraine headaches. This medication is available as a prescription drug, thus limiting its reach to patients that cannot afford the drug. This in turn, is expected to restrain growth of the Divalproex sodium market.

Request for Sample Copy of Research Report: https://www.worldwidemarketreports.com/sample/197632

Side effects such as pancreatitis during medication as well as severe stomach pain, chills, constipation, nausea, vomiting, fever, and lightheadedness are associated with this drug. Furthermore, dullness, tiredness, weakness or feelings of sluggishness, changes in mental status, low body temperature, or vomiting may result in hyperammonemic encephalopathy, which in turn, poses as major factor hampering growth of the Divalproex sodium market.
Divalproex sodium is available under the following different brand names: Depakote, Depakote ER, and Depakote Sprinkles.
Increasing prevalence of bipolar disorder and epilepsy, globally is increasing the demand for therapies and medications, in turn, fueling growth of the Divalproex sodium market. This drug is especially prescribed for manic episodes among people suffering from bipolar disorder. The dosage required is Depakote initial dose of 750 mg/day orally in divided doses, without exceeding 60 mg/kg/day.

Get Best Discount On This Report:
https://www.worldwidemarketreports.com/discount/197632

The drug is also being adopted to monitor liver function tests (LFT's). Conversion from Depakote to Depakote ER is observed by administering Depakote ER once daily using a dose 8-20% higher than the total daily dose of Depakote. It causes low serum albumin levels, which increases unbounding of the drug. People suffering from epilepsy are indicated with dose of 50-100 mcg/mL total valproate. While for mania is 50-125 mcg/mL total valproate; maximum concentrations generally achieved within 14 days. These factors in turn, are responsible for the increased demand for Divalproex sodium, in turn, driving growth of the Divalproex sodium market.

In 2016, a novel divalproex sodium (DS) enteric-coated capsule was prepared in the lab with the help of high performance liquid chromatography (HPLC) assay method for DS. The uniformity, release curve, and release characteristics in different solvents were demonstrated by the results, showing that the assay developed was specific, rapid, and reliable enough to be used in determining DS in vitro accurately.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:
Mr. Shah
Worldwide Market Reports
Tel: +1 415 871 0703
Email: sales@worldwidemarketreports.com

This release was published on openPR.